ArticleFrontiers in pharmacology2026
Prediction model of thrombocytopenia on patients using linezolid: a ranked-based covariate selection with multi-center data.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thrombocytopenia is a common adverse reaction of linezolid, often leading to severe complications. It is challenging to externally validate directly apply developed in other countries. We aim to develop and validate a risk prediction model of linezolid-associated thrombocytopenia (LAT) tailored to Vietnamese setting and to construct a simplified risk score calculation to support clinical decision-making. Materials and Methods: Data was collected retrospectively from three large hospitals in Northern Vietnam. We selected inpatients treated with linezolid from November 2019 to March 2023. Potential predictors were chosen based on literature review and clinical experts' opinions. Final predictors were selected using Bayesian model selection. Thrombocytopenia was defined as platelet count value ≤112.5 G/L and a decrease more than 25% from the baseline. A multivariable logistic regression model was constructed to predict the occurrence of LAT. The final model was further validated using internal-external cross-validation. Results: Of 776 patients included, 247 patients (31.8%) developed LAT. Logistic regression model selection indicated that the risk predictors were age, duration of linezolid ≥14 days, baseline platelet count, creatinine clearance, sepsis, cirrhosis, continuous renal replacement therapy (CRRT) and heparin use. The model had moderate discrimination, with area under the curve (AUC) of 0.77 (95% confidence interval (CI): 0.72-0.83). Model calibration was good, with calibration-in-the-large and calibration slope of 0.00 (-0.38 to 0.38), and 0.92 (0.59-1.26) respectively. A risk score scale was established, with the optimal cut-off value being 23 points. Patients were categorised based on this score into three groups: low risk (-1 to 13 points), moderate risk (14-22 points) and high risk (≥23 points). Conclusion: Our newly developed risk prediction model demonstrated moderate discriminatory ability in predicting the occurrence of LAT. From there, a simplified risk score was constructed to facilitate its applicability in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.